Innovate Biopharmaceuticals, Inc. (INNT)
| Market Cap | 23.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 41.33M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 1, 2020 |
| Last Price | $0.560 |
| Previous Close | $0.560 |
| Change ($) | 0.000 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 0.551 - 0.720 |
| Day's Volume | 1,547,785 |
| 52-Week Range | 0.370 - 1.670 |
News
Innovate Biopharmaceuticals, Inc. (INNT) CEO Sandeep Laumas on Q1 2019 Results - Earnings Call Transcript
Innovate Biopharmaceuticals, Inc. (INNT) CEO Sandeep Laumas on Q4 2018 Results - Earnings Call Transcript
About INNT
9 Meters Biopharma operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long... [Read more...]
| Industry Biotechnology | Founded 2012 |
| CEO Sandeep Laumas | Employees 8 |
| Stock Exchange NASDAQ | Ticker Symbol INNT |